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Summary Haematoporphyrin derivative (HPD) photodynamic therapy (PDT) may have clinicial application
in the management of patients with retinoblastoma. Heterotransplantation of retinoblastoma cells into the
anterior chamber of the nude mouse eye and the subsequent growth of small tumour masses has provided a
model for evaluation of various therapeutic modalities. Ninety-four evaluable xenograft tumours in 54 nude
mice were randomized to receive one of the following treatments: cyclophosphamide (CPM) alone, HPD-PDT
alone, CPM followed by HPD-PDT, HPD-PDT followed by CPM, or saline control. Responses were
demonstrated after CPM treatment in all three relevant groups. However, HPD-PDT was found to be
ineffective either alone or as a contributor in the double modality treatment groups. The small tumour
masses treated can be demonstrated histologically to be avascular. It is proposed that although the
same retinoblastoma cells in different circumstances are responsive to HPD-PDT, no clinical response is
demonstrable utilizing this model, due to the absence of tumour vascularity.
Haematoporphyrin derivative (HPD) photodynamic therapy
(PDT) is being applied to the treatment of malignancy in an
increasing number of clinical and experimental situations.
Retinoblastoma (RB) is the most frequently encountered
eye cancer in childhood and is bilateral in one third of
cases (White, 1983c). Although RB is highly curable by
enucleation and/or radiotherapy, the morbidity of current
treatment has made HPD-PDT an appealing prospect in the
management of early, and particularly bilateral RB. The
relatively easy access of light to the intraocular lesion
(Gomer et al., 1984) and documented in-vitro responsiveness
of RB to HPD-PDT (Sery, 1979) have encouraged further
research.
A xenograft model has been developed whereby human
RB can be studied heterotransplanted into the anterior
chamber of the nude (athymic) mouse eye (Gallie et al.,
1977). Necrosis was documented histologically in very
advanced tumours after HPD injection followed by PDT in
the mouse (Benedict et al., 1980b). The model was adapted
to allow the study of early, small tumours in situ and
document changes in growth pattern as a measure of
responsiveness (White et al., 1983a). Various chemothera-
peutic agents have been successfully tested in this adapted
model (White et al., 1983b). Cyclophosphamide (CPM) was
the most effective of the currently available chemo-
therapeutic agents. Given this background, a series of
experiments were performed to evaluate responsiveness of
RB to HPD-PDT and the potential interaction between
chemotherapy and HPD-PDT in the model. It became
apparent that poor vascularization of the xenograft played
an important role in determining response to HPD-PDT.
Materials and methods
The model
A number of human RB cell lines have been established and
maintained by the heterotransplantation of cells from
enucleated eyes of children with RB (Benedict et al., 1980a).
Cells in suspension (105 ml-1) were injected under micro-
scopic visualization directly into the anterior chamber of the
mouse eye (total volume injected less than 5 microlitres).
Swiss background nude (athymic) mice of both sexes were
utilized. The animals were maintained and treated in a
protected, sterile environment and were allowed food and
water ad libitum. Their weight was monitored weekly.
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In the model, tumour growth is usually observed after a
latency of 3-4 weeks and can then be monitored to progress
until the front of the eye is filled by RB. The tumour is
graded 1-4 according to the proportion of the anterior
chamber filled by RB. As the volume of the anterior
chamber is estimated to be 4-8pl, a grade I tumour,
occupying one quarter of that space, would be expected to
have a volume of 1-2p1. Grade 2 (2 quarters) is 2-4 u1, grade
3 (3 quarters) is 3-6pl and grade 4 is 4-8pl, or more due to
expansion by the tumour. In therapeutic assays treatment is
commenced when a tumour is graded 1 or 2 (Figure 1). The
eyes are observed weekly under a dissecting microscope with
light (ether) anaesthesia. Tumour grades are documented
serially and relative responses are expressed as time in weeks
taken to progress from grade I or 2 to grade 4.
HPD-PDT delivery system
Monochromatic red light (630nm) was generated using a
tunable Kiton-red dye, model 375 laser pumped by a model
164, 5-watt argon laser (Spectra-Physics, Inc., Mountain
View, CA). A 200jpm quartz fibre was used to deliver the
laser output to the treatment room. The mice were anaesthe-
tised with pentobarbital, the eyes were proptosed by digital
pressure and light was applied to an area of 4mm diameter
which included the whole of the mouse eye. The light
wavelength was documented with a scanning mono-
chromator (model H-20, American ISA, Metuchen, NJ), and
a light dose rate was measured by a thermopile (model 210,
Coherent, Inc., Palo Alto, CA).
The dose rate was 200mWcm 2 (power 25mW, area
0.126cm2). Treatment for 375 sec achieved a dose of
75Jcm-2. This was the highest evaluable dose as pilot data
utilizing 100 or 150Jcm-2 in the presence of HPD (but not
in controls) produced intense ocular or periocular inflam-
mation and therefore obstructed observation of the tumour
in situ.
Mouse treatment experiments
Fifty-four nude mice bearing 94 evaluable tumours (40 mice
bilateral tumours, 14 mice unilateral tumours), derived from
the LARB-69 xenograft line (Benedict et al., 1980a) were
randomized into one of 5 treatment groups (Table I). Group
I received CPM 200mgkg-1 i.p. once. Group 2 received
HPD (concentrated sterile solution, obtained from Oncology
Research and Development Inc.) 20mgkg-1 i.p. once and
PDT, 630nm red light, 75Jcm 2 at 24h. Group 3 received
CPM as in group 1, followed one week later by HPD-PDT
as in group 2. Group 4 received HPD-PDT as in group 2,
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followed one week later by CPM as in group 1. Group 5
acted as controls and were given i.p. saline.
HPD-PDT cytotoxicity to cells in culture
The LARB-69 cells were grown in a culture system designed
for the maintenance of RB cells in vitro and previously
published (Bogenmann et al., 1983). In brief, a suspension of
RB cells (single cells and small clumps) were prepared from in
vivo tumours and plated onto 20 dishes containing cultured
rat smooth muscle cells (SMC) as substrate. The culture
medium consisted of DMEM (Dulbecco's modified Eagle
medium, Grand Island Biological Co., Santa Clara, CA)
supplemented with 10% human serum, 100U penicillin ml- 1,
100Mg steptomycinml-I and 4mM glutamine, and was
changed every third day. After 6 days, growth was
established in chains and aggregates of RB cells. Since the
attachment to the SMC was loose, they were then readily
dissociated into suspension with DMEM and 1% foetal calf
serum (FCS) by pipetting.
After 2 washes, the cells were resuspended and aliquoted
into 20 equal one ml volumes in DMEM and 1% FCS. Four
aliquots were replated untreated onto the SMC culture
system as described. The remaining 16ml were incubated
with HPD, 30 jgml-1, in 37°C, for 1 h, in darkness and then
washed twice to remove unbound HPD. Sixteen 60 mm Petri
dishes were plated (one ml each) and exposed to red light as
follows: 4 aliquots min, 4 aliquots 3min, 4 aliquots 10min,
and 4 aliquots were kept in darkness as further control.
Subsequently, the cells were replated onto the SMC culture
system and all 20 dishes were monitored daily (day 3-7) for
Figure 1 White light (a) and fluorescence (b) photographs of a
mouse eye with grade 2 tumour growth (arrows), 24h after
injection of HPD. In (b) the HPD was activated using violet
light (406.7-413.1 nm) from a Krypton laser. Fluorescence is
documented by using a 590nm cut off filter to remove light
below this wavelength. Both the tumour and the periorbital
tissues are shown to contain HPD.
cell growth and viability. Dishes were kept in darkness.
Comparative viability was assessed by serial direct
observation ofcell growth in all dishes as a function of time.
The light source used was a parallel series of soft white, 30
watt, fluorescent bulbs (Sylvania, F30T12), enclosed on top
with a sheet of clear plexiglass filtered with a milar film
(Rubylith SR-3, Ulano Corp., Brooklyn, NY) as previously
published (Gomer et al., 1983). A treatment stand allowed
the dishes to be placed 5cm above the light source. The light
intensity at the treatment site was 0.35mWcm-2 and the
delivered spectrum was 570nm to 650nm with a peak output
at 620nm.
Results
Mouse treatment experiments
In Table I the five treatment groups are summarized and the
relative tumour progression, from grade 1 or 2 at the start of
treatment (or the start of the first treatment in the sequential
treatment groups) to grade 4, is documented in weeks.
Control tumours progressed to rapidly fill the eye (mean 3.3
weeks, s.d. 1.2 weeks). Consistent with prior data, the CPM
produced a significant reduction in tumour growth expressed
as delay in achieving grade 4. However, HPD-PDT either
alone or in sequence before or after CPM was found to be
ineffective and did not influence the outcome. Therefore,
HPD-PDT alone produced results comparable to control
saline treatment and HPD-PDT added before or after CPM
produced the same results as can be attributed to CPM
alone. No mice were found to lose more than 10% of their
weight from the beginning of the experiment.
HPD-PDT cytotoxicity to cells in culture
Daily observations of the 20 dishes in culture revealed viable
cells for up to 7 days after treatment in the 'no HPD-no
PDT' controls (4 plates), in the 'yes HPD-no PDT' controls
(4 plates), and in the 4 plates exposed to light for only 1 min.
However, no viable cells were identified by day 3 after
treatment in the dishes where exposure to light had been
continued for 3min (4 dishes) or 10min (4 dishes).
Discussion
The model reliably demonstrated the responsiveness of RB
to CPM. This serves as a positive control in the therapeutic
experiments. On the other hand, HPD-PDT did not
influence tumour growth in any of the three treatment
groups where it was included.
The most likely explanation for failure of response to
HPD-PDT of the human RB in this xenograft is poor
vascularization of early, small tumours grown in the anterior
chamber of the mouse eye. We have been able to document
in histologic specimens of eyes enucleated at the various
grades that early growth occurs as an avascular cluster or
Table I Responses to treatment in five groups. Tumour growth is
expressed as time interval in weeks required to progress from grade
1 or 2 (start of treatment) to grade 4
Tumour growth
Group Mice Tumours Treatment mean (weeks) s.d.
1 7 14 CPM 6.7 0.9
2 9 17 HPD-PDT 3.5 1.8
3 7 12 CPM then 8.3 3.1
HPD-PDT
4 8 12 HPD-PDT 7.1 1.2
then CPM
5 23 39 CONTROL 3.3 1.2
CPM - cyclophosphamide; HPD - haematoporphyrin derivative;
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nodule of RB cells (Figure 2). Subsequent vascularization
occurs as tumour begins to fill the anterior chamber (grade
4) and accounts for the histologic responses in advanced
tumours of LARB-69 and other RB cell origin, reported in
prior studies (Benedict et al., 1980b). In the current experi-
ment, when tumours progressed to grade 4 we were able
to confirm increased necrosis after exposure to HPD-PDT,
relative to untreated tumours of the same grade, even in eyes
that had proved resistant at an earlier grade of growth.
However, early tumours removed and examined histo-
logically after HPD-PDT showed only minimal centrilobular
necrosis, consistent with that same finding in totally
untreated tumours.
It was important to further confirm that the LARB-69
used in these experiments had not acquired HPD-PDT
resistance. For this reason, in vitro treatment was carried out
and response was documented. With this limited aim, the in
vitro data are purely comparative and no quantitative profile
of cell growth was obtained. Although a number of variables
limit the direct comparison of the in vitro system to the
intraocular model, one can at least conclude that the LARB-
69 cells were sensitive to HPD-PDT in vitro in a manner and
to a degree similar to other cultured cells. In fact, there has
not been documentation of any cell line totally resistant to
HPD-PDT in culture.
Although the poor vascularity of early tumour growth is
implicated in the failure of HPD-PDT, it was important to
exclude the possibility that the mechanism is entirely due to
the peculiarity of the model, viz. that there is no access of
HPD to the tumour cells via the aqueous fluid in the
anterior chamber. We have been able to show by fluorescent
photography that HPD is present in the early tumour, albeit
not preferentially concentrated by comparison to surround-
ing tissues (Figure 1). These tissues are hypopigmented in the
nude mouse and readily demonstrate the presence of HPD
fluorescence. In prior studies we have analysed the
distribution of 3H-HPD in nude mice (Gomer et al., 1982).
Eyes with tumours had up to four fold increased con-
centration 3H-HPD than control eyes (tumours were too
small to be measured independently). Furthermore, recent
data utilising a larger, rabbit model demonstrated that HPD
measured by fluorescence is present maximally in vascular
ocular structures (iris, choroid, vascularised tumour), is
absent in avascular structures (lens, cornea, vitreous), but is
also detectable in the aqueous fluid (Gomer et al., 1985). It
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Figure 2 Cross-sectional view of the anterior chamber of the
nude mouse eye limited by the cornea (above) and lens (below).
The chamber contains small tumour masses growing in a lobular
pattern with some necrosis centrally No vasculature is visible in
the tumour. (H&E stain).
would appear, therefore, that the aqueous fluid and
avascular tumours contained within the anterior chamber do
not preferentially concentrate HPD but do have access to its
delivery. Given the size of the xenografted tumour and
limitations of current technology, direct measurement of
HPD in tumour tissue is not obtainable.
There have been various hypotheses suggested for the
importance of vascularity in the mechanism of HPD-PDT.
At the least, it is an efficient method of delivery of both
HPD and oxygen to the tumour cells (Parrish, 1983). 'Leaky'
vasculature may allow HPD to enter the extracellular fluid
space and in this regard it is noteworthy that tumour
vasculature may be 'leakier' than normal (Straight et al.,
1985). Furthermore, tumours may lack the mechanism
required to efficiently clear the HPD retained therein
(Bugelski et al., 1981). Bugelski has shown in autoradio-
graphic studies that 3H-HPD was distributed at a ratio of
5:1 in favour of the vascular stroma in experimental animal
models and that vascular damage occurred within 15 minutes
after HPD-PDT (Bugelski et al., 1981).
Although tissue hypoxia may have a role in the
mechanism of vascular effects, the oxygen tension required
for response to HPD-PDT (rather than cure) is small.
Furthermore, in our model continued tumour growth was
documented, chemotherapeutic agents were effective and
radiation therapy has also been shown to produce a response
(Gallie et al., 1982). It is unlikely, therefore, that oxygen
tension was a limiting factor.
The most challenging hypotheses suggest that the primary
target for HPD-PDT tumour kill is the vascular endothelial
cell rather than the tumour cell itself. Evidence in favour of
a vascular collapse being the initial event in PDT induced
tumour necrosis has been advanced by various workers
based on observations in both human and animal tumour
studies (Bugelski et al., 1981; Bicher et al., 1981; Selman
et al., 1985; Henderson et al., 1985; Straight et al., 1985).
Elegant in vitro models have confirmed these observations
and have strengthened the arguments in favour of a primary
vascular mechanism (Star et al., 1984; Straight et al., 1985).
Henderson was able to demonstrate that clonogenicity of
tumour cells following HPD-PDT was proportionate to the
time the cells remain in situ before being excised and plated.
Therefore, a 10 hour delay in excision produced a one
hundred fold reduction in clonogenicity, a finding
comparable to that produced by vascular deprivation due to
death of the host (Henderson et al., 1984). Berenbaum et al.
(1986) have produced convincing evidence for a primary
endothelial site of action intracranially, a particularly
important finding in view of the expected barriers to
penetration of HPD and other chemicals into the brain and
brain tumours. Furthermore, authors have expressed doubts
regarding the often quoted view that tumours and therefore
tumour cells have the capacity to preferentially retain HPD
(Straight et al., 1985; Winkelmen et al., 1985).
Several of the mechanisms suggested for the role of
tumour vascularity in HPD-PDT effectiveness may be
relevant to the model utilized in our studies. In the
knowledge that failure of delivery of HPD was not solely
responsible and that the same cells in a vascular situation are
responsive to the same treatment, we are able to add to the
body of evidence that tumour vascularity may play a pivotal
and possibly primary role in HPD-PDT. The ability to
achieve photo-cytotoxicity in vitro with this cell-line, as in
others, points to multiple, dose dependent mechanisms of
HPD-PDT effect. It is likely that in high concentrations
HPD-PDT is photocytotoxic directly to tumour cells, while
in vivo tumour kill may depend to variable degrees on the
role of the vascular endothelium as a primary target.
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